Boston Therapeutics Exhibits at Obesity Week 2013 Conference

MANCHESTER, NH--(Marketwired - Nov 14, 2013) - Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"), an innovator developer of drugs that address diabetes using complex carbohydrate chemistry, will provide information about PAZ320, an investigational non-systemic chewable tablet, that when taken as an adjunctive therapy, helped patients with Type II diabetes manage the post meal elevation of their blood sugar in a Phase IIa clinical trial, at booth #127 at the inaugural Obesity Week 2013 Conference in Atlanta, Georgia, November 13 to 15.

Edward Shea, Vice President of Business Development, Boston Therapeutics, Inc., commented, "Our participation in Obesity Week 2013 -- the world's largest event on obesity treatment and prevention -- will further demonstrate Boston Therapeutics' commitment to those patients suffering from obesity and one of its devastating complications: diabetes."

About Obesity Week

Obesity Week 2013 is the inaugural event co-locating the American Society of Metabolic and Bariatric Surgery (ASMBS) and The Obesity Society (TOS) annual meetings. In doing so, more than 60 years of combined experience in the study of obesity and its management are reflected in an interdisciplinary program from which all attendees will benefit. Both organizations have worked to give attendees the greatest value for their registration fee as they are able to attend both ASMBS and TOS Scientific Sessions. These sessions will include debates, key lectures, keynote speakers, networking/social events, oral presentations, panel discussions, paper and video sessions, poster presentations, partner and organizational symposiums. For more information, visit www.obesityweek.com.

About PAZ320

PAZ320 is a non-systemic chewable complex carbohydrate-based compound designed to reduce post-meal elevation of blood glucose. PAZ320 is a proprietary polysaccharide designed to be taken before meals and works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes that break down carbohydrates into glucose and release it into the bloodstream.

About Boston Therapeutics, Inc.

Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: BTHE) is an innovator in designing drugs using complex carbohydrate chemistry. The Company's product pipeline is focused on developing and commercializing therapeutic molecules that address Type 2 diabetes, including: PAZ320, a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation, and IPOXYN, an injectable anti-necrosis drug specifically designed to treat lower limb ischemia associated with diabetes. More information is available at www.bostonti.com.

Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that our plans, expectations and goals regarding the clinical trials are subject to factors beyond our control and provide no assurance of FDA approval of our drug development plans. Our clinical trials may not produce positive results in a timely fashion, if at all, and any necessary changes during the course of the trial could prove time consuming and costly. We may have difficulty in enrolling candidates for testing, which would affect our estimates regarding timing, and we may not be able to achieve the desired results. Any significant delays or unanticipated costs in the trials could delay obtaining meaningful results from Phase II and/or preparing for Phase III with the current cash on hand.

Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse effect on our ability to achieve revenues from this proposed indication. Plans regarding development, approval and marketing of any of our drugs, including PAZ320, are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. To date, we have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be affected by our ability to manage costs and finance our continuing operations. For a discussion of additional factors affecting our business, see our Annual Report on Form 10-K for the year ended December 31, 2012, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.